Your HIV labs — the numbers, in plain English.

The first time most people see their own HIV lab report, it reads like a spreadsheet written in a language nobody offered to teach them. There are two or three numbers everybody talks about, a dozen more nobody explains, and a scattering of little red H and L flags next to values that may or may not matter. If you have ever stared at that page and thought am I doing badly? — you are in extremely normal company.

Here is the frame worth carrying into this article: your labs are not a report card, and they are not a verdict. They are a shared instrument panel. They exist so that you and your clinician can see the same information at the same time and make decisions together — whether to keep a regimen, whether to add a screening test, whether something unrelated to HIV needs attention. Once you know what each dial is for, the page stops being intimidating and starts being useful.

The map — what your labs are actually for

HIV lab work does four jobs, and almost every test on your report belongs to one of them.

One: measure the virus. That is the viral load — plasma HIV RNA. It tells you and your clinician whether your treatment is working right now. It is the single most action-oriented number on the page.

Two: measure your immune system. That is the CD4 count and CD4 percentage. It tells you how much immune damage happened before treatment and how well your immune system is rebuilding. It matters enormously at diagnosis and matters progressively less once you have been suppressed for a couple of years.

Three: make sure the medication is a good fit for your body. That is the kidney panel, the liver enzymes, the blood count, the lipid panel, glucose, and urinalysis. None of these are "HIV tests." They are safety monitoring, the same way anyone on a long-term medication gets periodic bloodwork.

Four: catch the things that are more common, or more consequential, when you live with HIV. That is hepatitis screening, tuberculosis screening, STI screening, cervical and anal cancer screening, cardiovascular risk assessment, and vaccine status. This is the largest category and the one most often skipped, and it is where the guidelines have moved the most in recent years.

Two national documents drive nearly all of it. The Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV govern the HIV-specific and safety-monitoring labs; the laboratory testing section — the source of the well-known monitoring grid clinicians call Table 3 — was last reviewed in September 2025.1 Everything broader than that lives in the Primary Care Guidance for Persons With Human Immunodeficiency Virus, published in Clinical Infectious Diseases in 2024 by an HIV Medicine Association and Infectious Diseases Society of America panel led by Michael Horberg and Melanie Thompson.7 The DHHS guidelines explicitly hand off to that document for primary-care labs, which is why the two fit together rather than compete.

One line from the DHHS monitoring table is worth taping to your fridge: clinicians should use clinical judgment to determine monitoring frequency for an individual person based on clinical needs.1 The schedules below are defaults, not rules. If yours differs, the right move is to ask why — not to assume something is wrong.

The baseline panel — what gets drawn when you enter care

The first blood draw after a diagnosis is the biggest one you will ever have, and it can feel like an ambush. It helps to know that the list is standardized, published, and finite. Here is what the DHHS laboratory testing section calls for at entry into care, and why each item is on the list.1

The HIV-specific tests

• HIV antigen/antibody test — drawn at entry if the diagnosis has not already been documented, or if you tested anonymously and there is no record in your chart.7
• Quantitative HIV RNA (viral load) — your starting point, and the number every later result is compared against.
• CD4 count with percentage — the IDSA and HIVMA panel specifically asks for the percentage alongside the absolute count, because the percentage is the steadier of the two.7
• Genotypic resistance test for the protease and reverse transcriptase genes, to make sure the first regimen is one your particular virus is susceptible to. An integrase-gene genotype is added only if transmitted integrase resistance is suspected, or if you have a history of integrase inhibitor exposure — including long-acting cabotegravir used for PrEP, or an integrase inhibitor taken for post-exposure prophylaxis.1
• HLA-B*5701 — a one-time genetic test, done only if abacavir is being considered. The result goes in your record permanently; it never needs repeating.1

The safety and organ-function tests

• Complete blood count with differential — red cells, white cells, platelets.
• Basic metabolic panel — sodium, potassium, bicarbonate, chloride, BUN, creatinine, glucose, and a creatinine-based eGFR. If you have chronic kidney disease and are taking tenofovir disoproxil fumarate, serum phosphorus is added.1
• ALT, AST, and total bilirubin — liver enzymes and liver clearance.
• Lipid profile — fasting if practical; a random panel with abnormal results should be repeated fasting.7
• Random or fasting glucose, plus a baseline hemoglobin A1c drawn before treatment starts.7
• Urinalysis — looking for protein and glucose in the urine, which are early signals of kidney stress.
• Pregnancy test for people of childbearing potential, at entry and at treatment initiation.1

The coinfection and exposure screens

• Hepatitis B: three tests, not one. Surface antigen (HBsAg), surface antibody (HBsAb), and total core antibody (HBcAb) together tell you whether you have hepatitis B, are immune to it, or need vaccination. If HBsAg is positive, a hepatitis B viral load follows.7
• Hepatitis A IgG — immunity check, because hepatitis A vaccination is recommended for everyone who is not already immune.7
• Hepatitis C antibody, with an HCV RNA test if the antibody is positive. Hepatitis C RNA rather than antibody is the right screening test if exposure within the last six months is suspected, if you previously cleared an infection, or if your CD4 count is under 200.7
• Tuberculosis screening by skin test or interferon-gamma release assay. This is the detail most worth remembering: for a person living with HIV, an induration greater than 5 mm counts as positive — a lower threshold than for the general population — and a positive screen leads to a chest radiograph.7
• Syphilis, gonorrhea, and chlamydia at entry into care, with gonorrhea and chlamydia tested by nucleic acid amplification at every site of sexual contact.7
• Measles, mumps, and rubella antibodies if you were born in 1957 or later; varicella serology may also be considered.7
• If your CD4 count is low: toxoplasma IgG under 200 cells/µL, and a serum cryptococcal antigen under 100 cells/µL.7
• G6PD screening in some circumstances — particularly for people assigned male at birth of African, Mediterranean, or Asian descent, before starting medications like dapsone or primaquine that can trigger red-cell breakdown in people with the deficiency.7

Two things are notably not on the routine list. Herpes simplex IgG and cytomegalovirus IgG are not recommended as general screening tests. Neither are inflammatory biomarkers: the IDSA and HIVMA panel states plainly that there are no data supporting the use of inflammatory biomarkers for assessing comorbidity risk.7 If you have seen an HIV wellness clinic advertise a panel of inflammation markers, that is why your HIV clinic does not order them.

Routine testosterone testing is likewise not recommended. A morning serum testosterone is appropriate for adult cisgender men with specific symptoms — decreased libido, erectile dysfunction, reduced bone density or low-trauma fracture, hot flashes, or sweats — ideally drawn before 10 a.m. and confirmed on a repeat if low. The guidance also flags that direct free testosterone analogue assays are unreliable and should not be used.7

Viral load — what "undetectable" actually means

Viral load is a count of HIV genetic material in a milliliter of blood plasma. It is the number that answers "is this working," and it is the reason HIV treatment can be managed with a blood draw a few times a year rather than a hospital stay.

Undetectable is a property of the test, not a cure

"Undetectable" means the assay used on your sample could not find virus above its lower limit of detection. Those limits vary: the most commonly used assays report down to somewhere between 20 and 50 copies/mL.7 DHHS describes optimal viral suppression as a confirmed viral load below the lower limit of detection of available assays — generally under 20 copies/mL, depending on the assay.2 So "undetectable" on a report from one lab is not numerically identical to "undetectable" from another. It is not a grade. It means below the floor of this particular instrument.

Two practical consequences. First, if your clinic switches labs, your "detectable/undetectable" line may appear to change even though nothing about your virus did. Second, commercially available HIV-1 RNA assays do not detect HIV-2 viral load — relevant for the small number of people living with HIV-2.2

The 200-copy line, and why it is the number that matters for prevention

Two hundred copies/mL is the most consequential threshold in HIV medicine, and it does double duty.

Clinically, DHHS defines virologic failure as the inability to achieve or maintain a viral load below 200 copies/mL — a threshold chosen deliberately because it eliminates most apparent viremia caused by blips or assay variability.2 For prevention, the same number is the U=U threshold. The DHHS panel's recommendation is explicit: all people with HIV should be informed that maintaining a plasma viral load below 200 copies/mL — including any measurable value below that threshold — with antiretroviral therapy prevents sexual transmission of HIV.5 CDC likewise defines viral suppression as fewer than 200 copies of HIV per milliliter of blood.6

The evidence base behind that is unusually strong. HPTN 052 randomized people living with HIV with CD4 counts of 350 to 550 in mixed-status relationships to early versus delayed treatment; the 2016 final analysis reported no phylogenetically linked transmissions when the partner living with HIV had a suppressed viral load.5 PARTNER, PARTNER2, and Opposites Attract then followed 548 heterosexual and 1,481 male–male mixed-status couples across 144,631 episodes of condomless vaginal or anal sex with the partner living with HIV virally suppressed below 200 copies/mL — and observed no phylogenetically linked transmissions.5 CDC's summary of the PARTNER data reports a transmission risk estimate of 0.00 per 100 couple-years, with the upper confidence bound narrowing to 0.21 when PARTNER2 and Opposites Attract data on condomless anal sex among male couples are combined.6

Two honest caveats that belong in the same breath, both straight from the guidelines. When you start treatment, use another prevention method for at least the first six months and until a viral load below 200 copies/mL is documented; many experts recommend confirming sustained suppression first.5 And maintaining suppression does not prevent transmission or acquisition of other sexually transmitted infections, which is why STI screening stays on the schedule for everyone sexually active.5

Blips, low-level viremia, and failure — three different things

These get conflated constantly, and the distinction is the difference between a shrug and a regimen change. DHHS defines them separately:3

• Blip — after suppression, a single detectable result followed by a return to suppression. DHHS says a blip is not usually predictive of virologic failure.2
• Low-level viremia — a confirmed viral load above the assay's detection limit but still under 200 copies/mL. The data on whether this predicts failure are genuinely conflicting, and DHHS says so.2
• Virologic rebound — after suppression, a confirmed result at or above 200 copies/mL.
• Virologic failure — inability to achieve or maintain a viral load under 200 copies/mL. The IDSA and HIVMA framing is two consecutive results above 200 copies/mL.7

Blips are common enough that the guidelines quantify them. With some earlier regimens, up to 16% of people taking their medication consistently may experience a blip in a given year, and most blips represent normal biological fluctuation or laboratory artifact rather than missed doses.5 In PARTNER and PARTNER2, transient elevations above 50 but below 200 copies/mL occurred during 6% and 4% of total follow-up time — and still, no linked transmissions.5 That is the single most reassuring statistic in this article, and it is worth rereading if a blip has ever frightened you. Our companion page on viral blips goes deeper.

Persistent viremia is a different matter, and here the guidelines are direct: viral loads sustained at or above 200 copies/mL are often associated with viral evolution and the accumulation of resistance mutations, and this is particularly common above 500 copies/mL.3 That is the actual reason clinicians push on a persistently detectable result — not to scold anyone, but because staying detectable is how a regimen loses future options. And note what the guidelines say not to do: stopping or interrupting treatment during virologic failure is explicitly not recommended.3

How often, and what counts as a real change

Standard timing: viral load at entry into care, again at treatment initiation, then 4 to 8 weeks after starting. If it is still detectable at that point, repeat every 4 to 8 weeks until it is below the assay's limit. Then every 3 to 4 months, extending to 6-month intervals for people who have been suppressed longer than a year with stable immune status.12 Suppression is usually reached 8 to 12 weeks after starting treatment.2

And the number that saves a lot of unnecessary worry: the minimum statistically significant change in viral load is threefold, or 0.5 log10.2 A move from 40 to 80 copies is within assay noise. It is not a trend.

CD4 — count, percentage, and when your clinician stops watching it

CD4 cells are the immune cells HIV targets, and the CD4 count is the closest thing to a measure of immune reserve. It answers a different question than viral load: not "is treatment working" but "how much ground was lost, and how much has come back."

Why the percentage is often the better number

The absolute CD4 count is not directly measured. It is calculated from your total white blood cell count and lymphocyte percentages — which means it inherits every fluctuation those values have. DHHS lists the culprits: bone-marrow-suppressive medications, chronic corticosteroids, and acute infections all move the absolute count around. Splenectomy or HTLV-1 coinfection can push it misleadingly high. In all of those settings, the CD4 percentage stays stable and may be the more appropriate parameter for assessing immune function.2 The IDSA and HIVMA guidance agrees that the percentage is somewhat less variable, and gives useful anchors: counts of 200 and 500 cells/µL correspond roughly to CD4 percentages of 14% and 29%.7

The other number that prevents unnecessary alarm: a significant change in CD4 is roughly a 30% shift in the absolute count, or 3 percentage points in the CD4 percentage.2 A drop from 640 to 580 is noise. Draw the same blood on a different morning and you might get either number.

What immune recovery actually looks like

An adequate CD4 response to treatment is an increase of 50 to 150 cells/mm³ in the first year, weighted toward the first three months, followed by roughly 50 to 100 cells per year until it plateaus. The rise can be blunted if your baseline CD4 was very low or if you started treatment at an older age.2 That last point deserves saying gently: a slower climb is a known biological pattern, not a sign you are doing something wrong.

The monitoring taper — and why it is good news

CD4 monitoring is designed to wind down. DHHS lays out the sequence: at entry into care, again about three months after starting treatment, then every 3 to 4 months during the first one to two years if your CD4 is under 300, or every 6 months if it is 300 or above with a suppressed viral load. After one to two years with consistently suppressed viral load and a CD4 count of 300 or higher, CD4 monitoring becomes optional unless clinically indicated.2 The IDSA and HIVMA guidance puts the off-ramp slightly differently: after two years on suppressive therapy with a CD4 of 300 to 500, annually — and above 500 cells/µL, monitoring is optional.7

If your clinician stops ordering CD4 counts, that is a milestone, not neglect. DHHS notes that reducing CD4 monitoring from every 6 months to every 12 could save roughly $10 million a year in the United States — money that does more good elsewhere in HIV care.2

About the CD4/CD8 ratio

You will see the CD4/CD8 ratio discussed in research papers and in community forums as a marker of immune health, and it is a real biological signal. It is also, per both guidelines, not something to monitor routinely. DHHS recommends against monitoring CD8, CD19, and other lymphocyte subsets, on the grounds that their clinical usefulness has not been established and the testing adds cost.2 The IDSA and HIVMA panel is equally plain: measuring the CD8 count and the CD4/CD8 ratio is not considered necessary, because the results are not used in clinical decision making.7 If your report includes a ratio because the lab's panel bundles it, that is fine — it just is not a number anyone should be treating.

The resistance genotype — reading your virus's rap sheet

A genotype sequences your virus and looks for mutations known to reduce susceptibility to specific antiretroviral drugs. It is the reason first regimens work as reliably as they do.

Resistance testing is recommended at entry into HIV care to guide the initial regimen, with genotypic testing preferred over phenotypic. And one line matters more than the rest for anyone anxious about waiting: treatment should not be delayed while awaiting resistance results.4 Starting now and adjusting later is the guideline-endorsed path.

What the test can and cannot see

• It needs virus to sequence. Genotypic assays generally require a viral load of at least 500 to 1,000 copies/mL. Conventional Sanger sequencing of the reverse transcriptase, protease, and integrase genes typically returns results in one to two weeks.4
• Minority variants hide. Drug-resistant virus making up less than about 10% to 20% of your circulating population probably will not be detected.4 This is why a "no resistance detected" result is reassuring rather than absolute.
• Timing is everything on a failing regimen. Resistance testing should be done while you are still taking the regimen that is failing, or within four weeks of stopping it. For long-acting cabotegravir and rilpivirine, test regardless of how long ago the last injection was.3
• Suppressed and switching? If your viral load is undetectable there is nothing to amplify, so a standard genotype cannot be run — which is why proviral DNA assays come up in that conversation.4

On a detectable result while taking treatment, the thresholds are graded: testing is strongly recommended above 1,000 copies/mL, recommended between 501 and 1,000, and should be considered between 201 and 500 with the honest caveat that it may not succeed at those levels.4 Transmitted resistance — acquiring virus that already carries a resistance mutation — does happen, and some mutations remain detectable for years in people not taking treatment.4 That is the whole rationale for testing before the first prescription rather than after the first disappointment.

Two specialty tests you may see mentioned. Tropism testing is done only if a CCR5 antagonist is being considered, or on virologic failure while taking one. Phenotypic testing — growing your virus against drugs in a lab rather than reading its sequence — is added to a genotype for known or suspected complex resistance patterns, not used first-line.14

Kidney labs — eGFR, creatinine, and the flag that is usually fine

Kidney monitoring gets real attention in HIV care for good reason: kidney function is abnormal in up to 30% of people with untreated HIV, and HIV-associated nephropathy is a relatively common cause of end-stage renal disease, particularly among Black people living with HIV.7

The numbers on your report:

• Serum creatinine — a muscle waste product cleared by the kidneys. Higher generally means slower clearance.
• eGFR — estimated glomerular filtration rate, calculated from creatinine. This is the number clinicians actually watch.
• Urinalysis — for protein and glucose in the urine. Protein in urine is often the earliest sign of kidney stress, and both DHHS and the primary care guidance want urine protein and glucose assessed before and during treatment with tenofovir alafenamide or tenofovir disoproxil fumarate.17

Frequency: the basic metabolic panel is drawn at entry, at treatment initiation, again at 4 to 8 weeks, then every 6 to 12 months — moving to every 3 to 4 months if you have preexisting conditions or added risk.1 Urinalysis is annual, and more often if clinically indicated. The IDSA and HIVMA guidance asks for kidney function at least every 6 months for people with diabetes, hypertension, hepatitis C, advanced HIV disease, a genetic predisposition, or exposure to potentially nephrotoxic medications including tenofovir.7

What triggers escalation: proteinuria of grade 1 or higher on dipstick, or reduced kidney function, should prompt a nephrology referral, quantification of the protein loss, a renal ultrasound, and possibly a biopsy. Annual urinalysis for protein is specifically emphasized for people with increased kidney-disease risk — CD4 under 200, viral load above 4,000, diabetes, hypertension, or hepatitis C coinfection.7

Liver labs — enzymes, hepatitis, and what a mild elevation means

The liver panel on your report is doing two jobs at once: watching for medication effects, and watching for viral hepatitis.

• ALT and AST — enzymes released when liver cells are stressed or damaged. Mild elevations are common and have a long list of ordinary causes, including alcohol, fatty liver, other medications, and recent intense exercise.
• Total bilirubin — a breakdown product the liver clears. Some antiretrovirals, notably atazanavir, raise bilirubin harmlessly.
• Alkaline phosphatase — from liver and bone; useful context when bilirubin or the transaminases are moving.

Timing follows the metabolic panel: ALT, AST, and total bilirubin at entry, at treatment initiation, at 4 to 8 weeks, then every 6 to 12 months — every 3 to 4 months if you have a preexisting liver condition, added risk, or hepatitis B coinfection.1 The IDSA and HIVMA schedule is a chemistry panel one to two months after starting or changing treatment, then every 6 months.7

Hepatitis B — and the switch nobody warns you about

Hepatitis B monitoring has a wrinkle worth knowing in advance. Tenofovir, in both its forms, treats hepatitis B as well as HIV. If you are living with hepatitis B and your regimen changes to one without tenofovir alafenamide or tenofovir disoproxil fumarate, hepatitis B can reactivate. DHHS therefore calls for repeating hepatitis B serology if you are not immune and are switching to a regimen without either drug — and also before starting direct-acting antiviral treatment for hepatitis C, because of the same reactivation risk.17 Periodic retesting may also be considered if you are not immune and have ongoing exposure risk.1

Hepatitis C — a curable coinfection

The message here is short and good. Curative therapy should be offered to everyone with active hepatitis C, and a hepatitis C RNA test at least 12 weeks after finishing treatment confirms a sustained response — the definition of cure.7 Annual hepatitis C antibody screening is recommended for people with an increased likelihood of exposure, including people who inject drugs, cisgender men who have sex with cisgender men, and transgender women.7

If liver enzymes are up and hepatitis is ruled out, the next path is a fatty liver workup: ultrasound, MRI, or CT, and if steatosis is present, a fibrosis assessment using FIB-4, elastography, or biopsy. Weight reduction is the cornerstone of treatment, and steatohepatitis or established fibrosis warrants a hepatology referral.7

Metabolic labs — lipids, glucose, weight, and the A1c asterisk

This is the section of your labs that has the least to do with HIV and the most to do with how long you live. Modern treatment has made cardiometabolic health the main event.

Lipids

A lipid profile is drawn at entry and at treatment initiation, repeated 3 to 6 months after viral suppression is achieved, then annually if you are 40 or older or taking a statin, and every one to three years if you are under 40 and not on a statin. Repeat sooner if your cardiovascular risk factors change.1 Fasting is optimal; an abnormal random panel should be repeated fasting.7

Worth knowing why HIV complicates the picture: untreated HIV tends to lower total, HDL, and LDL cholesterol; starting treatment — especially with boosted protease inhibitors — raises LDL and improves HDL, though HDL does not fully normalize.7 So a "worse" lipid panel after starting treatment is often a partial return toward your pre-HIV baseline rather than a new problem.

Glucose — and the hemoglobin A1c asterisk

This is the detail most likely to surprise you, and it runs against the reflex to trust A1c above all else. A random or fasting glucose is drawn at entry, at treatment initiation, and every 6 months.1 But the DHHS monitoring table carries an explicit footnote: hemoglobin A1c is no longer recommended for diagnosing diabetes in people with HIV who are taking antiretroviral therapy, in line with American Diabetes Association guidance.1

The IDSA and HIVMA guidance explains the nuance and gives the practical rule. Draw a baseline A1c along with glucose before starting treatment. After treatment begins, A1c becomes insensitive and may significantly underestimate diabetes risk — but an A1c above 6.5% is still a reliable criterion for diagnosis. If the A1c is below 6.5%, fasting plasma glucose is the better screening test. Once diabetes is diagnosed, A1c is monitored at least every 6 months with a goal below 7%.7

Translation for your next visit: a normal A1c on treatment does not rule out diabetes, and asking for a fasting glucose is a reasonable request rather than an odd one.

Weight and waist

Two measurements that are not blood tests but belong on the same page. Weight should be recorded at every visit, and waist circumference — an indirect marker of visceral fat — measured annually. Counseling on diet, exercise, and alcohol should begin when treatment starts and continue at every visit.7 And one point that matters for anyone who has gained weight on a modern regimen and is thinking about switching: current data do not support changing a regimen for weight gain alone.7 That is a conversation, not a foregone conclusion.

Hormones

Testosterone is checked for symptoms, not screened routinely, as described above.7 For transgender and gender-diverse people receiving gender-affirming hormone therapy, hormone monitoring follows the relevant gender-affirming care guidance, and osteoporosis screening is individualized to risk rather than assigned by a single age cutoff.7

Bone and heart — DXA timing and the statin conversation

Bone density

People living with HIV carry higher rates of bone mineral density loss.7 Baseline bone densitometry by DXA is recommended for postmenopausal cisgender women and for men aged 50 and older; screening for transgender people follows national recommendations based on individualized osteoporosis risk.7 If a DXA shows osteoporosis, or if you have had a fragility fracture, treatment follows. Where vitamin D deficiency and osteopenia coexist, correcting the deficiency comes first, with a follow-up DXA a year later to see how bone responded.7 Annual frailty screening is also worth considering after age 50.7

Cardiovascular risk — what REPRIEVE changed

REPRIEVE is the trial that rewrote this part of HIV care. It randomized 7,769 people living with HIV at low-to-moderate cardiovascular risk, all taking antiretroviral therapy, to daily pitavastatin 4 mg or placebo. Median age was 50; median CD4 count was 621. The trial was stopped early for efficacy after a median 5.1 years of follow-up. Major adverse cardiovascular events occurred at 4.81 per 1,000 person-years with pitavastatin versus 7.32 with placebo — a hazard ratio of 0.65, 95% CI 0.48 to 0.90, p=0.002.9 In the longer follow-up reflected in current guidance, that is a 36% reduction in major cardiovascular events over a median 5.6 years.8

Guidance has kept moving since. In February 2024 the DHHS panel, working with the American College of Cardiology, the American Heart Association, and the HIV Medicine Association, issued statin recommendations for people living with HIV based on REPRIEVE. Then, in March 2026, an updated ACC/AHA/Multisociety dyslipidemia guideline was published containing recommendations specifically for people with HIV — and the DHHS panel retired its own statin section and now defers to that guideline. The current bottom line: for people with HIV aged 40 to 75, statin therapy is recommended for primary prevention of atherosclerotic cardiovascular disease. Under 40, the data are insufficient for an HIV-specific recommendation, and the approach is shared decision-making.8

Two things make this more than a checkbox. First, standard risk calculators miss HIV-related risk. The DHHS statement lists factors not captured by traditional equations: prolonged duration of HIV, delayed treatment initiation, long periods of detectable virus or difficulty with adherence, low current or lowest-ever CD4 count (for example under 350 cells/mm³), exposure to older antiretrovirals with cardiometabolic toxicity, and hepatitis C coinfection.8 NIH analyses from REPRIEVE found that risk was underestimated in several groups, including Black people, cisgender women, people from high-income regions, and people whose HIV was not virally suppressed.18

Second, statins and antiretrovirals interact. Drug–drug interactions may require a dose adjustment, a different statin, or closer monitoring — which is precisely why the choice belongs to the clinician who can see your whole medication list.8 Pitavastatin was chosen for REPRIEVE partly because it does not interact with antiretrovirals.9

Cancer screening — mostly the same, with important exceptions

Start with the reassuring part. Screening for prostate, breast, lung, and colon cancer for people living with HIV is not different from the general population; follow U.S. Preventive Services Task Force and American Cancer Society recommendations.7 Biennial mammography from ages 40 to 74. Low-dose CT lung screening for ages 50 to 80 with a 20-pack-year history who currently smoke or quit within 15 years — and people living with HIV appear to get the same mortality benefit when CD4 is above 500 and treatment adherence is good.7

What changes is vigilance and two specific screening programs. Lung, anal, and myeloma cancers may appear at younger ages in people living with HIV, and rates of oral, pharyngeal, and kidney cancer are higher. Higher CD4 counts (at or above 350 cells/µL) and maximal viral suppression are associated with lower five-year mortality among people living with HIV who receive any cancer diagnosis.7 HPV and hepatitis B vaccination are frontline cancer prevention here — cervical, anal, head and neck cancers, and liver cancer respectively.7

Anal cancer screening — what ANCHOR proved

For decades there was no randomized evidence that finding and treating anal precancer prevented anal cancer. The ANCHOR trial settled it. Conducted at 25 U.S. sites, it randomized people living with HIV aged 35 and older with biopsy-proven anal high-grade squamous intraepithelial lesions to treatment — mostly office-based electrocautery — or to active monitoring. Of 4,459 randomized, 4,446 were analyzed. Over a median 25.8 months, 9 anal cancers occurred in the treatment group (173 per 100,000 person-years) versus 21 in the monitoring group (402 per 100,000 person-years) — a 57% lower rate of progression to anal cancer (95% CI 6 to 80; p=0.03).11 The National Cancer Institute's announcement summarized it the same way and noted that the finding provided the rationale for screening, not just treatment.12

That evidence produced actual screening programs. The IDSA and HIVMA guidance now recommends an annual digital anorectal examination for people living with HIV whether or not high-resolution anoscopy is available, and anal cytology — Pap testing with HPV co-testing rather than HPV testing alone — for transgender women and cisgender men over 35 who have sex with cisgender men, and for all other people living with HIV over 45, where there is access or referral capacity for high-resolution anoscopy and treatment. Low-grade lesions or worse are referred for anoscopy; high-grade lesions are treated, ideally with hyfrecation, and monitored; any anal cancer goes to surgical oncology.7 Age thresholds in the U.S. clinical guideline literature align closely: screening from age 35 for cisgender men living with HIV who have ever had sex with men, transgender women, and transgender men who have had sex with men, and from 45 for others — with the option to reduce screening from annual to every three years after two consecutive negative results for both high-risk HPV and high-grade dysplasia.14 Dedicated anal cancer screening guidance for people with HIV has continued to develop in the peer-reviewed literature since ANCHOR.13

The access problem is real and worth naming: high-resolution anoscopy requires trained clinicians and specialized equipment, and there are not enough of either. If you are told screening is unavailable locally, the fallback in the guidance is an annual rectal exam with referral for standard anoscopy if the screen is abnormal.7

Cervical cancer screening — more often, and never aging out

Cervical screening for people living with HIV differs from the general population in two important ways. Ages 21 to 29: an annual cervical Pap test; after three consecutive normal results, the interval extends to three years. HPV co-testing is not recommended in this age group. Age 30 and above: annual Pap testing, with the same three-normal-results rule, or a three-year interval after a single Pap if both cytology and HPV co-testing are negative. HPV16 or HPV16/18 on co-testing prompts colposcopy referral. Abnormal cytology means colposcopy or a repeat Pap in 6 to 12 months.7

And the difference that matters most: unlike people without HIV, there is no age limit for cervical Pap screening. Screening does not stop at 65.7

Liver cancer and prostate

Hepatocellular carcinoma screening — ultrasound every 6 months, with or without alpha-fetoprotein — is recommended for anyone with cirrhosis from any cause, chronic hepatitis B, or a history of hepatitis C, treated or not, with stage F3 or F4 fibrosis.7 For prostate cancer, shared decision-making about PSA is recommended for ages 50 to 69 with at least a 10-year life expectancy, and consider offering it from 45 to 49 for people who are Black or of African descent or who have a first-degree relative with prostate cancer.7 For transgender people with prostates, PSA is unreliable on androgen blockers or after orchiectomy, and after vaginoplasty a neovaginal and rectal exam is used to examine the prostate — with the reminder that cancer follow-up remains lifelong for organs that are still present.7

STI screening — sites, frequency, and the test-of-cure detail

STI screening is part of routine HIV care rather than an add-on, and the DHHS prevention guidance is explicit that maintaining a viral load below 200 copies/mL does not prevent other STIs, which is why routine screening is recommended for everyone sexually active.5

The IDSA and HIVMA schedule:7

• At entry into care: gonorrhea, chlamydia, and syphilis for everyone. Trichomonas by vaginal or cervical nucleic acid amplification test for people having receptive vaginal sex.
• All sites of sexual contact. Gonorrhea and chlamydia testing by nucleic acid amplification at oral, anal, urethral or urine, and vaginal or neovaginal sites. A urine-only test misses throat and rectal infections, which are frequently asymptomatic. Self-collected swabs, done correctly, are as sensitive as clinician-collected ones and may make the visit more acceptable.
• At least annually for asymptomatic sexually active people — gonorrhea, chlamydia, and syphilis, plus trichomonas for people having receptive vaginal sex.
• Every 3 to 6 months for people with multiple or anonymous partners, depending on sexual activities, recent STIs in you or a partner, and local community prevalence.
• Rescreen at 3 months after treatment for gonorrhea, chlamydia, syphilis, or trichomonas, because reinfection rates are high.
• Pharyngeal gonorrhea gets a test of cure at 7 to 14 days, by nucleic acid amplification or culture — with the caveat that testing at 7 days produces more false positives. A positive result after treatment should be cultured, and positive cultures sent for susceptibility testing.
• Syphilis follow-up: everyone diagnosed should be assessed for eye, ear, and neurologic involvement. A lumbar puncture is indicated for neurologic findings, but not for isolated eye or ear symptoms. Nontreponemal titers are followed after treatment, with a lumbar puncture if titers rise fourfold without evidence of reinfection, and consideration of spinal fluid examination and retreatment if titers do not fall fourfold by 24 months.
• In pregnancy: chlamydia, gonorrhea, and syphilis at the first prenatal visit and at 28 weeks, with syphilis again at delivery; trichomonas offered at the first visit. Partners should be offered screening and treatment.

Because gonorrhea resistance is increasing, the guidance says to consult CDC STI treatment recommendations frequently rather than relying on memory.7 Tuberculosis screening also belongs on the recurring list: annually for people with ongoing risk — including incarceration, congregate living, homelessness, or travel to high-incidence countries — and repeated after CD4 rises above 200 if the initial screen was negative during advanced immunosuppression.7

Vaccines — the HIV-specific differences

Vaccine schedules for people living with HIV differ from the general adult schedule in a handful of specific, memorable ways. The CDC adult immunization schedule is the master document, and the IDSA and HIVMA guidance translates it for HIV care — including the reminder to check ACIP recommendations and the opportunistic infection guidelines frequently, because this list changes.157

Reading your actual report — reference ranges and false alarms

Knowing what the tests mean is half the job. The other half is decoding the document your lab actually sends.

Five things about the page itself

• The reference range is a population range, not your target. It typically describes where about 95% of a reference population falls — which means roughly one in twenty healthy results sits outside it by definition. An H or L flag means "outside the usual range," not "abnormal for you."
• Viral load is reported in more than one way. You may see copies/mL, a log10 value, or both. Because a real change requires a threefold or 0.5-log10 shift, log values make trends easier to read than raw copy counts.2
• "Not detected," "<20," and "target not detected" are all versions of undetectable — the wording depends on the platform, and the number after the "<" is the assay's floor, which differs between labs.7
• CD4 has two values. The absolute count and the percentage. If they disagree — the count dropped but the percentage held — the percentage is often the more trustworthy of the two, because the absolute count is calculated and inherits fluctuations from your white cell count.2
• Results arrive at different times. Viral load, CD4, and chemistries usually come back within days; a resistance genotype typically takes one to two weeks.4 A partially populated report is normal, not an omission.

Out-of-range values that are often not a problem

• Creatinine up, eGFR down, shortly after starting treatment. Cobicistat, dolutegravir, bictegravir, and trimethoprim affect creatinine secretion and can raise the value without changing actual kidney function.7
• Elevated total bilirubin on certain regimens, without other liver abnormalities.
• A single detectable viral load after a long run of suppression. That is the definition of a blip, and DHHS says blips are not usually predictive of virologic failure.2
• A CD4 count that moved less than 30%, or a percentage that moved less than 3 points — within normal variability.2
• A normal A1c while taking treatment. Genuinely not proof of anything, because A1c is insensitive in this setting — which is the opposite of an alarm but still worth knowing.7
• Mildly low white cell counts if you take trimethoprim-sulfamethoxazole or another medication that can suppress cell lines; DHHS notes more frequent blood count monitoring is appropriate in that situation.1

Values that genuinely warrant a call

• A viral load at or above 200 copies/mL after you had been suppressed — that meets the definition of rebound and deserves a prompt conversation, not a wait for the next routine visit.3
• A CD4 count that falls below 200, which changes what infections you are screened and prophylaxed for.7
• New or worsening protein in the urine, or a real drop in eGFR sustained across draws.7
• Liver enzymes rising substantially rather than hovering.7
• A newly positive hepatitis B surface antigen or hepatitis C RNA.7

You are entitled to your results and to an explanation of them. If the portal releases numbers before your clinician has reviewed them — which is now common — it is entirely reasonable to send a message asking what a value means rather than sitting with it for three weeks.

The monitoring schedule — print this and bring it

This table consolidates the DHHS laboratory monitoring recommendations with the IDSA and HIVMA primary care schedule. It is a default, not a prescription: the DHHS table itself says clinicians should use clinical judgment to set frequency for an individual person based on clinical needs.1 Use it to ask questions, not to audit your clinician.

Compiled from the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV laboratory testing section (reviewed September 25, 2025) and the 2024 HIVMA/IDSA Primary Care Guidance for Persons With HIV. Not a substitute for your own care plan.

A Florida note on why the annual items matter

Florida has one of the largest HIV epidemics in the United States — in 2023 the CDC reported Florida among the highest state diagnosis rates for people aged 13 and older, at 22.7 per 100,000.17 The Florida Department of Health counted 128,497 people living with HIV in the state at the end of 2023, with 79% in care, 73% retained in care, and 70% virally suppressed below 200 copies/mL.16 Nationally, CDC data cited in the DHHS prevention guidance show 76.3% of people aged 13 and older with HIV engaged in clinical care during 2023 and 67.2% with a viral load below 200 copies/mL at their most recent measurement.5

Here is the detail from the Florida report that should change how you think about appointments: 90% of people retained in care in Florida had a suppressed viral load.16 Suppression is not mainly a matter of willpower or the right pill — it tracks with staying connected to care. Which makes the humble act of keeping a lab appointment one of the highest-leverage things on this page. If getting to care is the obstacle, start with our find care guide.

What to ask at your next visit

Bring five or six of these, not all of them. Written down beats remembered.

About the two headline numbers

• What is my viral load, and what is the lower limit of the assay this lab uses?
• Has my viral load changed by more than threefold since last time — or is this within normal variation?2
• What was my CD4 count and percentage, and are they telling the same story?
• Am I at the point where CD4 monitoring can become less frequent?2
• Am I under 200 copies/mL, and have I been for long enough that U=U applies to me?5

About safety monitoring

• Is my creatinine change from the medication's effect on creatinine secretion, or from my kidneys?7
• When did I last have a urinalysis checked for protein?
• Am I immune to hepatitis B? If not, should I be vaccinated — and does my regimen include tenofovir?1
• Do I need a fasting glucose rather than relying on my A1c?7

About prevention and screening

• Am I due for a statin conversation? I am aged 40 to 75 — what does the current guidance say for me?8
• Was my last gonorrhea and chlamydia screening done at all the sites relevant to me, not just urine?7
• Am I of an age for anal cancer screening, and does this clinic have access to high-resolution anoscopy or a referral pathway?7
• Am I up to date on hepatitis A and B, HPV (three doses), pneumococcal, mpox, and shingles vaccines?7
• Should I have had a DXA scan by now?7

About logistics

• Can I get my results released to the portal with a short note explaining them?
• Which results should prompt me to call rather than wait for the next visit?
• Can we consolidate my draws so I am not coming in separately for each test?

Next steps — three things that fit on an index card

One: find your last full lab report and read it once, slowly. Locate the viral load and its assay floor, the CD4 count and percentage, the eGFR, and the liver enzymes. Circle anything flagged. You are not diagnosing — you are building a baseline you personally understand, so the next report is a comparison rather than a first encounter.

Two: print the monitoring table and audit the annual items. Viral load and CD4 rarely get missed. Urinalysis, three-site STI screening, tuberculosis rescreening, cervical or anal cytology, DXA, the statin conversation, and vaccine catch-up frequently do. Circle what you cannot remember and hand the page over at your next visit — clinicians generally appreciate this rather than resent it.

Three: schedule the next draw before you leave the building. Florida's own data make the case better than any argument could: 90% of people retained in care in the state had a suppressed viral load.16 Staying connected is the mechanism.